Table 1.
The baseline characteristics of the CRC, healthy, and benign controls
| Characteristics | Cases (n = 455) | Healthy (455) | Benign (455) |
|---|---|---|---|
| Age (y, M with R) | 58 (24, 86) | 55 (22, 91) | 57 (17, 87) |
| Sex (male/female) | 252/203 | 252/203 | 252/203 |
| Location | |||
| Colon | 196 (43.1%) | ||
| Rectal | 259 (56.9%) | ||
| TNM stage | |||
| I | 49 (10.8%) | ||
| II | 164 (36.0%) | ||
| III | 177 (38.9%) | ||
| IV | 65 (14.3%) | ||
| Differentiation level | |||
| High | 14 (3.1%) | ||
| Middle | 370 (81.3%) | ||
| Low | 71 (15.6%) | ||
| Invasion depth | |||
| T1 | 10 (2.2%) | ||
| T2 | 55 (12.1%) | ||
| T3 | 70 (15.4%) | ||
| T4 | 320 (70.3%) | ||
| Lymph node metastasis | |||
| N0 | 232 (51.0%) | ||
| N1 | 151 (33.2%) | ||
| N2 | 72 (15.8%) | ||
| Neutrophil(*109/L) | 3.45 (2.73, 4.58)NA | 3.46 (2.79, 4.19) | 3.38 (2.70, 4.24) |
| Lymphocyte(*109/L) | 1.62 (1.30, 2.03)a, b | 1.95 (1.60, 2.32) | 1.74 (1.35, 2.11) |
| Fibrinogen(g/L) | 3.20 (2.66,3.72)a, b | 2.77 (1.40,2.24) | 2.70 (2.28,3.14) |
| Albumin(g/L) | 39.87 (37.23,41.86)a, b | 44.01 (42.01,45.78) | 41.38 (39.30, 43.53) |
| pre‐Albumin(mg/L) | 198.60 (153.20, 242.30)a, b | 248.55 (209.43, 286.14) | 266.50 (235.40, 301.90) |
| NLR (ratio) | 2.23 (1.62, 2.90)a, b | 1.81 (1.40, 2.24) | 1.94 (1.48, 2.61) |
| FAR (ratio) | 8.04 (6.59, 9.64)a, b | 6.38 (5.37, 7.47) | 6.49 (5.48, 7.71) |
| FPR (ratio) | 16.22 (11.79, 21.87)a, b | 11.16 (8.81, 14.53) | 10.00 (8.04, 12.35) |
| CEA (ng/mL) | 3.03 (1.52, 8.00)b | 1.38 (0.76, 2.21) | |
| CA199 (U/mL) | 15.93 (8.72, 29.51)b | 10.06 (6.64, 16.82) | |
Cases, patients with CRC; FAR, 100*Fibrinogen/Albumin; FPR, Fibrinogen/pre‐Albumin; Benign controls, patients with colorectal polyp; M with R, Mean with range; NA, not significant; NLR, neutrophil‐to‐lymphocyte ratio.
a
P < 0.05: cases vs healthy controls.
b
P < 0.05: cases vs benign controls.